Cargando…

Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados

OBJECTIVES: The increase in infections with multidrug resistant bacteria has forced to return to the use of colistin, antibiotic with known nephrotoxicity. The aim of the study is to determine the incidence of colistin nephrotoxicity nowadays. MATERIAL AND METHODS: Retrospective-observational-unicen...

Descripción completa

Detalles Bibliográficos
Autores principales: Espinoza, Cristian Rosas, Teller, José Manuel Caro, de la Calle, Guillermo Maestro, Loitegui, María Arrieta, Piquero, José Miguel Ferrari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876908/
https://www.ncbi.nlm.nih.gov/pubmed/33210107
http://dx.doi.org/10.37201/req/082.2020
_version_ 1783650057882435584
author Espinoza, Cristian Rosas
Teller, José Manuel Caro
de la Calle, Guillermo Maestro
Loitegui, María Arrieta
Piquero, José Miguel Ferrari
author_facet Espinoza, Cristian Rosas
Teller, José Manuel Caro
de la Calle, Guillermo Maestro
Loitegui, María Arrieta
Piquero, José Miguel Ferrari
author_sort Espinoza, Cristian Rosas
collection PubMed
description OBJECTIVES: The increase in infections with multidrug resistant bacteria has forced to return to the use of colistin, antibiotic with known nephrotoxicity. The aim of the study is to determine the incidence of colistin nephrotoxicity nowadays. MATERIAL AND METHODS: Retrospective-observational-unicentric study was collected hospitalized patients in intravenous colistin treatment during the years 2018-2019. Nephrotoxicity was defined according to the RIFLE scale. The variables to determine it were serum creatinine (sCr) and glomerular filtration (GF). The variables analyzed were age, sex, treatment duration, loading and cumulative dose, empirical/ targeted treatment, chronic kidney disease, concomitant use of intravenous contrast and nephrotoxic drugs. RESULTS: A total of 90 patients (60% men) were included, with an average age of 58.2±18.1 years. The mean duration of treatment was 9±8.3 days, with an average cumulative dose of 69.8±71MU. There were no differences between sCr and GF at the beginning and end of treatment. The incidence of nephrotoxicity was 1.73 cases/100 days of treatment (prevalence of 15.56%). CONCLUSIONS: Colistin nephrotoxicity has an important incidence, without developing severe illness.
format Online
Article
Text
id pubmed-7876908
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-78769082021-02-22 Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados Espinoza, Cristian Rosas Teller, José Manuel Caro de la Calle, Guillermo Maestro Loitegui, María Arrieta Piquero, José Miguel Ferrari Rev Esp Quimioter Original OBJECTIVES: The increase in infections with multidrug resistant bacteria has forced to return to the use of colistin, antibiotic with known nephrotoxicity. The aim of the study is to determine the incidence of colistin nephrotoxicity nowadays. MATERIAL AND METHODS: Retrospective-observational-unicentric study was collected hospitalized patients in intravenous colistin treatment during the years 2018-2019. Nephrotoxicity was defined according to the RIFLE scale. The variables to determine it were serum creatinine (sCr) and glomerular filtration (GF). The variables analyzed were age, sex, treatment duration, loading and cumulative dose, empirical/ targeted treatment, chronic kidney disease, concomitant use of intravenous contrast and nephrotoxic drugs. RESULTS: A total of 90 patients (60% men) were included, with an average age of 58.2±18.1 years. The mean duration of treatment was 9±8.3 days, with an average cumulative dose of 69.8±71MU. There were no differences between sCr and GF at the beginning and end of treatment. The incidence of nephrotoxicity was 1.73 cases/100 days of treatment (prevalence of 15.56%). CONCLUSIONS: Colistin nephrotoxicity has an important incidence, without developing severe illness. Sociedad Española de Quimioterapia 2020-11-19 2021 /pmc/articles/PMC7876908/ /pubmed/33210107 http://dx.doi.org/10.37201/req/082.2020 Text en © The Author 2020 https://creativecommons.org/licenses/by-nc/4.0/ Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Original
Espinoza, Cristian Rosas
Teller, José Manuel Caro
de la Calle, Guillermo Maestro
Loitegui, María Arrieta
Piquero, José Miguel Ferrari
Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados
title Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados
title_full Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados
title_fullStr Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados
title_full_unstemmed Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados
title_short Incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados
title_sort incidencia de nefrotoxicidad inducida por colistina intravenosa en pacientes hospitalizados
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876908/
https://www.ncbi.nlm.nih.gov/pubmed/33210107
http://dx.doi.org/10.37201/req/082.2020
work_keys_str_mv AT espinozacristianrosas incidenciadenefrotoxicidadinducidaporcolistinaintravenosaenpacienteshospitalizados
AT tellerjosemanuelcaro incidenciadenefrotoxicidadinducidaporcolistinaintravenosaenpacienteshospitalizados
AT delacalleguillermomaestro incidenciadenefrotoxicidadinducidaporcolistinaintravenosaenpacienteshospitalizados
AT loiteguimariaarrieta incidenciadenefrotoxicidadinducidaporcolistinaintravenosaenpacienteshospitalizados
AT piquerojosemiguelferrari incidenciadenefrotoxicidadinducidaporcolistinaintravenosaenpacienteshospitalizados